205 related articles for article (PubMed ID: 33012745)
1. Distinct clinical features and prognosis between persistent and temporary thyroid dysfunctions by immune-checkpoint inhibitors.
Inaba H; Ariyasu H; Iwakura H; Kurimoto C; Takeshima K; Morita S; Furuta H; Hotomi M; Akamizu T
Endocr J; 2021 Feb; 68(2):231-241. PubMed ID: 33012745
[TBL] [Abstract][Full Text] [Related]
2. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors.
Kurimoto C; Inaba H; Ariyasu H; Iwakura H; Ueda Y; Uraki S; Takeshima K; Furukawa Y; Morita S; Yamamoto Y; Yamashita S; Katsuda M; Hayata A; Akamatsu H; Jinnin M; Hara I; Yamaue H; Akamizu T
Cancer Sci; 2020 May; 111(5):1468-1477. PubMed ID: 32086984
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma.
Akturk HK; Couts KL; Baschal EE; Karakus KE; Van Gulick RJ; Turner JA; Pyle L; Robinson WA; Michels AW
JAMA Netw Open; 2022 Dec; 5(12):e2246400. PubMed ID: 36512357
[TBL] [Abstract][Full Text] [Related]
4. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
5. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
Yamauchi I; Yasoda A; Matsumoto S; Sakamori Y; Kim YH; Nomura M; Otsuka A; Yamasaki T; Saito R; Kitamura M; Kitawaki T; Hishizawa M; Kawaguchi-Sakita N; Fujii T; Taura D; Sone M; Inagaki N
PLoS One; 2019; 14(5):e0216954. PubMed ID: 31086392
[TBL] [Abstract][Full Text] [Related]
6. Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy.
Luongo C; Morra R; Gambale C; Porcelli T; Sessa F; Matano E; Damiano V; Klain M; Schlumberger M; Salvatore D
J Endocrinol Invest; 2021 Sep; 44(9):1927-1933. PubMed ID: 33576954
[TBL] [Abstract][Full Text] [Related]
7. Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes.
Lui DTW; Lee CH; Tang V; Fong CHY; Lee ACH; Chiu JWY; Leung RCY; Kwok GGW; Li BCW; Cheung TT; Woo YC; Lam KSL; Yau T
Endocr Pract; 2021 Sep; 27(9):886-893. PubMed ID: 33581327
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitor-induced hypothyroidism predicts treatment response in Japanese subjects.
Iwamoto Y; Kimura T; Dan K; Ohnishi M; Takenouchi H; Iwamoto H; Sanada J; Fushimi Y; Katakura Y; Shimoda M; Nakanishi S; Mune T; Kaku K; Kaneto H
Front Endocrinol (Lausanne); 2023; 14():1221723. PubMed ID: 37583431
[TBL] [Abstract][Full Text] [Related]
9. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors.
Mazarico I; Capel I; Giménez-Palop O; Albert L; Berges I; Luchtenberg F; García Y; Fernández-Morales LA; De Pedro VJ; Caixàs A; Rigla M
J Endocrinol Invest; 2019 Dec; 42(12):1443-1450. PubMed ID: 31093955
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
Kotwal A; Kottschade L; Ryder M
Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
[No Abstract] [Full Text] [Related]
11. Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients.
Baek HS; Jeong C; Shin K; Lee J; Suh H; Lim DJ; Kang MI; Ha J
BMC Endocr Disord; 2022 Apr; 22(1):89. PubMed ID: 35379219
[TBL] [Abstract][Full Text] [Related]
12. Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors.
Iwama S; Kobayashi T; Arima H
Endocrinol Metab (Seoul); 2021 Apr; 36(2):312-321. PubMed ID: 33934588
[TBL] [Abstract][Full Text] [Related]
13. Predictors of thyroid adverse events during cancer immunotherapy: a real-life experience at a single center.
Ruggeri RM; Spagnolo CC; Alibrandi A; Silvestris N; Cannavò S; Santarpia M
J Endocrinol Invest; 2023 Nov; 46(11):2399-2409. PubMed ID: 37076759
[TBL] [Abstract][Full Text] [Related]
14. Delayed-onset immune-related adverse events involving the thyroid gland by immune checkpoint inhibitors in combination with chemotherapy: a case report and retrospective cohort study.
Ueba Y; Yamauchi I; Hakata T; Fujita H; Okamoto K; Ikeda K; Ueda Y; Fujii T; Taura D; Inagaki N
Endocr J; 2023 Mar; 70(3):323-332. PubMed ID: 36464271
[TBL] [Abstract][Full Text] [Related]
15. Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study.
Wu L; Xu Y; Wang X; Cheng X; Zhang Y; Wang Y; Fan X; Zhao H; Liu H; Chai X; Zhang L; Wang M; Li N; Pan H; Lian X
Endocrine; 2023 Jul; 81(1):123-133. PubMed ID: 36867366
[TBL] [Abstract][Full Text] [Related]
16. The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders.
Ma C; Hodi FS; Giobbie-Hurder A; Wang X; Zhou J; Zhang A; Zhou Y; Mao F; Angell TE; Andrews CP; Hu J; Barroso-Sousa R; Kaiser UB; Tolaney SM; Min L
Cancer Immunol Res; 2019 Jul; 7(7):1214-1220. PubMed ID: 31088848
[TBL] [Abstract][Full Text] [Related]
17. Quantitation of cardiac troponin I in cancer patients treated with immune checkpoint inhibitors: a case-control study.
Ulndreaj A; Brinc D; Altan M; Pons-Belda OD; Fernandez-Uriarte A; Mu-Mosley H; Fattah F; von Itzstein MS; Soosaipillai A; Kulasingam V; Palaskas NL; Gerber DE; Diamandis EP; Heymach JV; Prassas I
Clin Chem Lab Med; 2023 Jan; 61(1):154-161. PubMed ID: 36287134
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors.
Yoon JH; Hong AR; Kim HK; Kang HC
Endocrinol Metab (Seoul); 2021 Apr; 36(2):413-423. PubMed ID: 33820396
[TBL] [Abstract][Full Text] [Related]
19. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
Bhatlapenumarthi V; Patwari A; Harb AJ
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
[TBL] [Abstract][Full Text] [Related]
20. Association between germ-line HLA and immune-related adverse events.
Jiang N; Yu Y; Zhang M; Tang Y; Wu D; Wang S; Fang Y; Zhang Y; Meng L; Li Y; Miao H; Ma P; Huang H; Li N
Front Immunol; 2022; 13():952099. PubMed ID: 36177028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]